Chinese biologics research, development and manufacturing company WuXi Biologics (Cayman) Inc (HKEX:2269) announced on Tuesday that it has commenced construction of a new modular drug product facility at its Contract Research, Development, and Manufacturing Organisation hub in Singapore.

The facility is to be developed in partnership with Sweden-based medical equipment manufacturer Pharmadule Morimatsu AB, a subsidiary of Morimatsu International Holdings Ltd (HKEX:2155). Under the collaboration, 470 prefabricated modules are being produced in Changshu City for delivery and installation at Tuas Biomedical Park.

Once completed, the 30,000-square-metre facility will feature three pre-filled syringe lines and two vial lines, supporting both liquid and lyophilised products across clinical and commercial stages.

The site will include centralised quality control laboratories and manufacturing science and technology labs, enhancing WuXi Biologics' end-to-end drug product service capabilities. A modular drug substance facility is also in design as part of the Singapore expansion.

As part of its sustainability commitment, WuXi Biologics intends to integrate solar power and advanced energy monitoring technologies.

The project supports the company's Global Dual Sourcing strategy of expanding global manufacturing capacity and improving supply chain flexibility.

The facility is expected to begin operations in 2027.